Anagrelide Hcl (anagrelide HCl)

Anagrelide is an imidazoquinazoline-derivative platelet-reducing agent.

Exact mechanism of action not fully elucidated; thought to reduce platelet counts in a dose-related manner by selectively inhibiting megakaryocyte maturation during postmitotic stage of development. Reduces size and ploidy of megakaryocytes, but does not appear to affect platelet function or bleeding time.

Acts selectively on megakaryocytes with minimal or no effect on other blood-cell precursors. Current data suggest no long-term leukemogenicity.

Inhibits phospholipase A2 and phosphodiesterase (PDE) type 3 activity in platelets; results in increased concentrations of cyclic adenosine monophosphate (cAMP). Such increases in cAMP may produce an anti-aggregating effect on platelets at dosages substantially higher than those required to cause thrombocytopenia.

Exerts positive inotropic and vasodilatory effects through inhibition of cAMP PDE type 3 in myocardium; such actions may result in adverse cardiovascular effects.

USES: Anagrelide is used to treat a certain blood disorder (thrombocythemia), which is caused by your bone marrow making too many platelets. Platelets are a blood cell that the body uses to form blood clots. Too many platelets can cause problems with your circulation, including unwanted blood clots and bleeding problems.

This drug reduces the number of platelets in the bloodstream by blocking their production.

Generic name: anagrelide HCl
Pronunciation: (an-AG-re-lide)

The following indications are listed for Anagrelide Hcl:

• Essential Thrombocytosis
• Thrombocytosis In Myeloproliferative Disease

Also known as: Essential Hemorrhagic Thrombocythemia, Essential Thrombocythemia, Hemorrhagic Thrombocythemia, Idiopathic Hemorrhagic Thrombocythemia, Idiopathic Thrombocythemia, Thrombocythemia In Myeloproliferative Disease, Thrombocythemia Primary.

No ICD codes are available for this drug.